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Transmural Infarction 
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Hamhurg, West Germany and Seattle, Washington 
To determine whether myocardial salvage after suc-
cessful intracoronary or intravenous thrombolysis is time 
dependent, the relation between left ventricular wall mo-
tion and the time to treatment was studied in 69 patients 
admitted less than 3 hours after onset of acute trans-
mural myocardial infarction (42 patients with reperfu-
sion by intracoronary streptokinase, 27 by intravenous 
urokinase). A similar significant relation between the 
time to treatment and the severity of regional hypoki-
nesia at follow-up was found in the intracoronary and 
intravenous groups. To better define this relation, par-
ticularly during the early phase of infarction, the groups 
were combined. 
In patients in whom thrombolytic treatment was ini-
tiated within 2 hours after symptom onset, wall motion 
Several studies (1-5) in patients with acute myocardial in-
farction have shown that left ventricular function signifi-
cantly improves after lysis of the coronary thrombus. These 
studies compared mean values of treated patients with those 
of untreated or unsuccessfully treated patients. In our ex-
perience, however, wall motion at the site of the infarction 
improves in only 40% of reperfused patients (6,7). 
Animal studies (8-15) have shown a significantly close 
relation between the size of the infarct and the duration of 
coronary artery occlusion. To determine whether the degree 
of myocardial salvage in patients is time dependent, we 
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at follow-up was within 2 standard deviations of the 
normal mean in 82% (14 of 17 patients). If treatment 
was started 2 to 5 hours after symptom onset, the prob-
ability of improved wall motion decreased to 46% (24 
of 52 patients, p < 0.025). The time/wall motion relation 
appeared to be independent of infarct location, angio-
graphically visible collateral vessels and the presence of 
subtotal coronary artery occlusion. The severity of hy-
pokinesia at follow-up study correlated with the mag-
nitude of peak serum creatine kinase (r = -0.71), in-
dicating that thrombolytic therapy initiated within 2 hours 
after the onset of symptoms improves regional left ven-
tricular function and reduces infarct size more than later 
therapy does. 
(J Am Coll CardioI1985;6:518-25) 
studied the relation between regional wall motion measured 
from acute and follow-up contrast cineangiograms and the 
time from the onset of symptoms until the initiation of 
thrombolytic therapy. If a close relation between these two 
variables exists, then an early time period may be defined 
during which there is a high probability that the patients 
will benefit from successful thrombolysis, and a later time 
period during which the probability of benefit is less. In the 
present study we determined the relation between the time 
from symptom onset until initiation of thrombolytic therapy 
and recovery of wall motion at the infarct site for both 
intracoronary and intravenous thrombolysis. 
Methods 
Patient selection. Sixty-nine patients (60 men, 9 women, 
age range 17 to 68 years) who met the following criteria 
were included in the study: I)Severe ischemic chest pain 
lasting for more than 30 minutes and hospital admission 
within 3 hours after the onset of symptoms; 2) more than 
2 mm ST elevation in two or more electrocardiographic 
leads; 3) age 70 years or younger; 4) no contraindications 
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against thrombolysis; and 5) availability of acute and follow-
up coronary and left ventricular contrast cineangiograms 
adequate for evaluation. 
These criteria were met by 42 patients admitted between 
October 1979 and August 1982, who underwent intracor-
onary thrombolysis and 27 patients admitted subsequently 
who underwent intravenous thrombolysis. The risks and 
benefits of thrombolytic therapy were explained to the pa-
tient or his relatives, or both, and written informed consent 
was obtained. 
For comparison, the data of 19 (10 streptokinase- and 9 
urokinase-treated) patients who never manifested reperfu-
sion or who had rethrombosis are also included. These pa-
tients were all enrolled in the study at the same time as the 
patients who had reperfusion under the same entry criteria 
and received the same treatment. 
Methods of thrombolysis. Intracoronary thrombol-
ysis. Cardiac catheterization and intracoronary administra-
tion of streptokinase were performed as previously described 
(16). An intravenous bolus of 10,000 U of heparin was 
injected. First, the unaffected, and then the infarct artery 
was visualized. Streptokinase was infused into the ostium 
of the coronary artery at 4,000 U/min until the artery began 
to open, and then at 2,000 U/min for at least 45 minutes 
after reperfusion or until a total dose of 250,000 U was 
given. At the end of the study, left ventricular angiography 
was performed at 50 framesls in the 30° right anterior oblique 
projection. Angiography was repeated at follow-up, usually 
before hospital discharge 2 to 3 weeks later. 
Intravenous thrombolysis. An intravenous bolus of 2 
million U of urokinase was administered in the emergency 
room (17). Patients then underwent immediate coronary and 
left ventricular angiography an average of 1.1 ± 0.6 hours 
after the urokinase injection. No heparin was administered. 
The patients were restudied 2 to 3 weeks later before hospital 
discharge. 
Analysis of coronary angiograms and left ventricular 
function. All angiograms were analyzed at the University 
of Washington. Identification of the infarct artery was based 
on the location of 1) ST elevation on the electrocardiogram, 
2) hypokinetic wall motion on the ventriculogram, and 3) 
residual stenosis or thrombotic material, or both, in the 
coronary artery. Coronary artery patency was defined as 
prompt and complete filling of the suspected infarct artery 
with good runoff of the contrast medium. Coronary angio-
grams were assessed by two independent observers. To mea-
sure left ventricular function, the cine films were projected, 
and the end-diastolic and end-systolic endocardial contours 
were traced from the frames with maximal and minimal 
volume, respectively, from a normal sinus beat that was not 
preceded by a premature beat. Measurement of the ejection 
fraction and of regional wall motion abnormality was per-
formed as previously described (7). Briefly, left ventricular 
chamber volume was calculated using the area-length method. 
MATHEY ET AL. 519 
IMPORTANCE OF EARLY THROMBOLYTIC THERAPY 
Wall motion was measured along 100 chords constructed 
perpendicular to a center line drawn midway between the 
enq-diastolic and end-systolic contours (Fig. I), and nor-
malized by the end-diastolic perimeter. Abnormality in 
chordal motion at the infarct site was expressed in units of 
standard deviations (SO) from the mean wall motion of 64 
normal patients. The selection criteria and description of 
this normal reference group has been previously described 
(7,18). Hypokinesia is indicated by negative values, hy-
Figure I. Centerline method of regional wall motion analysis. A, 
End-diastolic and end-systolic left ventricular endocardial contours 
and centerline (dotted) constructed by the computer midway be-
tween the two contours. B, Motion is measured along 100 chords 
constructed perpendicular to the centerline. C, Motion at each 
chord is normalized by the end-diastolic perimeter to yield a short-
ening fraction. Motion along each chord is plotted for the patient 
(solid line). The mean motion in the normal ventriculographic 
group (second dashed line) and I standard deviation above and 
below the mean (first and third dashed lines) are shown for 
comparison. D, Standardized motion. The wall motion of the pa-
tient is now plotted in units of standarq deviations from the normal 
mean (vertical dotted line). The normal ventriculographic group 
mean is represented by the horizontal dotte«iline. Vertical solid 
lines delimit the most hyperkinetic and ll10st hypokinetic parts of 
the anterior and inferior regions. 
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perkinesia by positive values. Regional wall motion was 
calculated as the mean motion of chords lying in the most 
hypokinetic 50% of the infarct artery territory, and ex-
pressed in SO/chord. The derivation of this method has been 
previously described (7,18). A normal, non-postpremature 
sinus beat was analyzable in both acute and follow-up ven-
triculograms in 21 patients treated with urokinase and in the 
follow-up study alone in 6 patients. 
The duration of ischemia in patients receiving intracor-
onary streptokinase was the time elapsed from symptom 
onset until angiographically documented reperfusion was 
achieved. The time to treatment was measured from symp-
tQm onset until thrombolytic therapy was initiated by either 
the intracoronary or the intravenous route. 
Results 
Intracoronary thrombolysis. Of the 52 patients, 42 
achieved sustained reperfusion after streptokinase infusion. 
The influence of time to thrombolytic therapy was analyzed 
in these 42 patients. The data of the other 10 (5 without 
reperfusion and 5 with rethrombosis) are included for com-
parison in Table I. Before thrombolysis, 7 (17%) of the 42 
patients had a subtotal coronary occlusion. Collateral vessels 
were visualized in only three of the patients. 
Global ejection fraction in patients with successful intra-
coronary thrombolysis was 56 ± 15% in the acute study 
and not significantly different at follow-up study (55 ± 
14%). Regional wall motion at the site of the infarct, how-
ever, improved significantly from an abnormally depressed 
value acutely (- 2.5 ± 1.0 SO/chord) to - I. 7 ± 1.2 
SO/chord at follow-up (p < 0.001). The time to initiation 
of intracoronary streptokinase infusion was 3.0 ± 1.0 hours 
(range 1.2 to 5.5); reperfusion was achieved 35 ± 15 min-
utes later. 
There was a significant relation between time to treat-
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ment and the severity of regional hypokinesia at the infarct 
site (Fig. 2). Compared with those treated later, patients 
treated less than 2 hours after symptom onset had signifi-
c'lntly greater improvement in regional and global left ven-
tricular function, and less severe hypokinesia at follow-up 
study (Table I). Eighteen (53%) of 34 patients treated 2 or 
more hours after symptom onset had severe residual hy-
pokinesia at follow-up study (as defined by hypokinesia 
more severe than 2 SO below normal), whereas only I (12%) 
of 8 patients treated earlier than 2 hours had residual ab-
normalities of wall motion at the infarct site. 
When patients whose pretreatment angiograms revealed 
only subtotal occlusions were eliminated from analysis, there 
still remained a significantly greater improvement in re-
gional wall motion in patients with total occlusion treated 
within 2 hours than in those treated later (2.1 ± 1.2 
[n = 6] versus 0.5 ± 1.0 [n = 30] SO/chord, P < 0.002). 
Intravenous thrombolysis. In patients with patent coro-
nary arteries after urokinase therapy, global ejection fraction 
did not change from acute (54 ± 10%) to follow-up (52 
± 11 %) study. Acute and follow-up values were also not 
significantly different from those of the intracoronary strep-
tokinase-treated group. 
Wall motion at the infarct site improved significantly 
from an abnormally depressed acute value (- 2.3 ± 1.1 
SO/chord) to follow-up value ( - 1.7 ± 1.3 SO/chord, P < 
0.02). There was no significant difference in either acute 
or follow-up wall motion values between the intracoronary 
streptokinase- and intravenous urokinase-treated groups. In-
travenous thrombolytic therapy was begun 2.0 ± 0.8 hours 
after symptom onset, significantly earlier than intracoronary 
streptokinase was given (p < 0.00 I). 
A significant relation between the time from onset of 
symptoms to initiation of intravenous urokinase and re-
gional wall motion was seen. Only in patients treated within 
2 hours was residual hypokinesia at follow-up significantly 
Table l. Effect of Intracoronary Streptokinase on Recovery of Left Ventricular Function (42 patients) 
Time to Treatment 
Regional hypokinesia (SO/chord) 
Acute 
Follow-up 
Delta 
p Valuet 
~ection fraction (%) 
Acute 
Follow-up 
Delta 
p Valuet 
Reperfused Patient Group 
<2h >2 h 
(n = 8) (n = 34) 
-2.9 ± 1.3 -2.4 ± 0.9 
-1.1 ± 1.0 -1.9 ± 1.2 
1.8 ± 1.3 0.5 ± 1.0 
0.006 0.011 
51 ± 16 57 ± 15 
58 ± 15 54 ± 14 
7 ± 10 -3 ± 9 
NS NS 
P Value* 
NS 
0.073 
0.002 
NS 
NS 
0.036 
Nonreperfused or 
Rethrombosed Patient Group 
(n = 10) 
-2.9 ± 0.7 
-3.1 ± 0.7 
-0.2 ± 0.8 
NS 
p Valuet 
NS 
0.001 
<0.001 
*Unpaired t test, patients treated <2 vs. >2 hours after onset of symptoms; tpaired t test, acute vs. follow-up study; :j:one way analysis of variance, 
reperfused <2 hours vs. nonreperfused or rethrombosed patient. Delta = difference between acute and follow-up values; SO = units of standard 
deviations. 
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Figure 2. Relation between time to treatment, plot-
ted on the x axis, and severity of residual hypo-
kinesia at follow-up, plotted on the y axis in 42 
patients with reperfusion by intracoronary strepto-
kinase. Time is expressed in hours from onset of 
chest pain to initiation of thrombolytic therapy. Hy-
pokinesia in the infarct region is expressed in stan-
dard deviations (SO) from normal. 
o 1 2 3 4 5 
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less severe than in patients without reperfusion (Table 2). 
Serial determinations of serum creatine kinase revealed that 
maximal creatine kinase was lower in patients who were 
treated within 2 hours and who had achieved reperfusion 
than in those treated later or who had not achieved reper-
fusion (Table 2). 
Combined intracoronary and intravenous patient 
group. To define the correlation between the time from 
onset of symptoms to the initiation of thrombolytic therapy 
and wall motion in the infarct area, particularly during the 
early phase, intravenous urokinase- and intracoronary strep-
tokinase-treated patients were considered as one group. In 
view of the similar relation between time to treatment and 
wall motion, it appears to be justifiable to combine the two 
treatment groups for this purpose. A treatment initiated within 
2 hours after the onset of symptoms was associated with a 
regional wall motion at follow-up within 2 standard deviac 
tions of normal in 14 (82%) of 17 patients. If treatment was 
administered 2 to 5 hours after symptom onset, the prob-
ability of improved wall motion decreased to 46% (24 of 
52 patients) (p < 0.025) (Fig. 3). To exclude the possibility 
that those patients who were treated early had an initially 
normal or less depressed wall motion, the change in regional 
wall motion from acute to follow-up study was plotted against 
the time to treatment, revealing a similar relation in patients 
who were treated early and late (Fig. 4). In addition, there 
was no correlation between the degree of acute wall motion 
abnormality and time to treatment (Fig. 5). To study the 
effects of infarct location on the time/wall motion relation, 
patients with an anterior and those with an inferior wall 
infarct were compared. There was no significant difference 
between these two groups (Fig. 3). 
Table 2. Effect of Timing of Intravenous Urokinase Therapy on Recovery of Left Ventricular Function (27 patients) 
Reperfused Patient Group Nonreperfused or 
Rethrombosed Patient 
Time to Treatment <2 h >2 h Group p Value* 
Regional hypokinesia (SD/chord) 
Acute - 2.0 ± 0.9(8)t -2.4 ± 1.1(13) - 2.9 ± 1.0(4) NS 
Follow-up -1.2 ± 1.4(9) -2.1 ± 1.0(18) -2.4 ± 0.9(9) <0.05 
Delta 0.8 ± 1.2(8) 0.4 ± 0.9(13) 0.1 ± 0.6(4) NS 
P Valuet 0.080 NS NS 
Ejection fraction (%) 
Acute 57 ± 7(8) 53 ± 11(13) 48 ± 8(4) NS 
Follow-up 54 ± 14(9) 48 ± 9(18) 48 ± 10(9) NS 
Delta -2 ± 12(8) - 3 ± 10(13) -I ± 5(4) NS 
P Valuet NS NS NS 
Maximal creatine kinase 714 ± 854(12) 1,471 ± 1,288(18) 1,973 ± 1,061(9) <0.01 
*Unpaired t test, treatment time <2 hours vs. nonreperfused or rethrombosed patient group; tpaired t test, acute vs. follow-up study; tnumbers in 
parentheses indicate the number of patients. Delta = difference between acute and follow-up values; NS = not significant. 
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Figure 3. Relation between time to thrombolytic 
treatment and severity of residual hypokinesia at 
follow-up in all 69 treated patients. See Figure 2 
for more detail. 
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Serum creatine kinase and regional left ventricular 
function. Figure 6 shows the relation between the severity 
of hypokinesia in the infarct region measured at follow-up 
and the peak creatine kinase value from serial studies in 
patients treated with urokinas~. There is a significant non-
linear correlation (r = -0.71). 
Discussion 
Comparison with previous studies. Our study shows 
that myocardial salvage after intracoronary and intravenous 
thrombolysis is time dependent in patients with acute an-
terior or inferior wall myocardial infarction. This is in ac-
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cordance with previous studies, which demonstrate a greater 
improvement in global left ventricular ejection fraction or 
a smaller infarcted area in patients who achieved reperfusion 
early. Schwarz et al. (2) found that in patients with a peak 
creatine kinase of less than 1,000 U/liter, improved global 
ejection fraction and a smaller thallium defect, the duration 
of symptoms was shorter than in patients without such im-
provement (3.9 versus 4.8 hours). Rentrop et al. (I) defined 
the critical time interval for myocardial salvage to be 4 
hours, during which the majority of patients will have im-
proved left ventricular function if thrombolysis is success-
ful. Schroeder et al. (19) reported a significant relation be-
tween the time to treatment and the "infarct area." In all 
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of these studies, however, very few patients were treated 
within 2 hours of onset of chest pain. which makes it difficult 
to define a time/salvage relation. 
Influence of factors other than time. In addition to the 
duration of symptoms, other factors such as the presence 
of subtotal occlusion (20) or of collateral vessels could be 
important determinants of myocardial salvage (21.22). In 
the group of 42 patients undergoing intracoronary throm-
bolysis who had a pretreatment coronary angiogram with 
visualization of the nonaffected coronary artery, both factors 
could be evaluated. In this series, the incidence of subtotal 
coronary occlusion was 12% (Fig, 2), These patients were 
distributed throughout the whole range of wall motion values 
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0 
Figure 5. Relation between time to thrombolytic 
treatment and severity of hypokinesia in the acute 
study in all 69 treated patients. Ie = intracoronary; 
IV = intravenous. See Figure 2 for more detail. 
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5 
HRS. 
* 
with no relation to the duration of symptoms. Angiograph-
ically visible collateral vessels were demonstrated in only 
three patients. Although the number of patients is limited. 
the data suggest that these factors cannot explain the good 
recovery in wall motion in patients treated within 2 hours 
after symptom onset. 
intracoronarv thrombolysis. In the intracoronary strep-
tokinase-treated group. reperfusion is well defined. The time 
from the onset of intracoronary streptokinase infusion to 
reperfusion is variable and ranges from 12 to 75 minutes. 
To determine whether this variability influences the time 
dependency of myocardial salvage. the effect of time to 
treatment versus time to reperfusion on recovery of regional 
* 
10,000 
Figure 6. Relation between severity of hypokinesia 
in the follow-up study and peak creatine kinase in 
21 patients. 
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left ventricular function was compared. With the exception 
of an expected parallel shift to the right, the relation was 
not significantly different. Thus, variability in the time from 
onset of treatment to reperfusion appears to have no sig-
nificant influence on this relation in this study. 
Intravenous thrombolysis. We then evaluated the rela-
tion between time to treatment and recovery of regional wall 
motion after thrombolytic therapy was administered intra-
venously in the emergency room and before angiography. 
Coronary angiography was performed immediately after 
thrombolytic therapy, 1.1 ± 0.6 hours after urokinase in-
jection. We observed the same correlation between time to 
treatment and regional wall motion in the groups with in-
travenous and intracoronary drug administration. Thus, be-
cause both groups were comparable with regard to the time 
dependency of myocardial salvage, they were analyzed to-
gether. The correlation between time to treatment and re-
sidual left ventricular wall motion became even more evi-
dent with a higher p value of less than 0.025. 
Role of degree of initial wall motion abnormality. To 
exclude the possibility that patients with good wall motion 
at follow-up had better wall motion initially than patients 
whose regional wall motion at follow-up was decreased 
more than 2 standard deviations below normal, the corre-
lation between time to treatment and change in regional wall 
motion between the acute and follow-up angiograms was 
also analyzed (Fig. 4) and a similar relation was found. 
Moreover, the degree of initial wall motion abnormality was 
independent of the time from the onset of symptoms to the 
onset of treatment. Thus, residual left ventricular wall mo-
tion at the site of the infarct indirectly reflects the amount 
of myocardium salvaged, and the recovery of ventricular 
function after thrombolytic therapy can be evaluated from 
a follow-up ventriculogram alone. As we have previously 
observed (7), the ejection fraction was too insensitive and 
failed to reflect the improvement in regional wall motion in 
the infarct site because of the concomitant decrease in the 
amount of acute compensatory hyperkinesia in the nonin-
farct region. 
Clinical implications. These data permit prediction of 
the results of thrombolysis in terms of myocardial salvage. 
However, reperfusion after intravenous thrombolysis should 
be verified promptly after treatment. Whether patients who 
subsequently have reperfusion will benefit from thrombol-
ysis cannot be concluded from our results. To achieve a 
residual abnormality in regional function that is less than 2 
standard deviations below normal in more than 80% of the 
patients, thrombolytic therapy should be started within 2 
hours. This appears to be independent of the presence of a 
subtotal occlusion or angiographically visible collateral ves-
sels. Between 2 and 5 hours after the onset of symptoms, 
the probability of myocardial salvage decreases to less than 
50%. 
The results of our study imply that thrombolysis should 
JACC Vol. 6, NO.3 
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be administered within 2 hours after the onset of symptoms 
to obtain maximal recovery of ventricular function. The time 
delay between the onset of symptoms and hospital admission 
is mainly caused by the patient's delay in seeking medical 
attention. Every measure that shortens this delay will help 
to increase the number of patients undergoing thrombolysis 
within 2 hours, thus increasing the benefit of thrombolysis 
in acute myocardial infarction. 
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